Medicare lists first ten drugs selected for pricing negotiations
wingedwolf/iStock via Getty Images
The Centers for Medicare and Medicaid Services (CMS) announced on Tuesday the first 10 Medicare Part D drugs it selected for pricing negotiations, a provision introduced as part of last year's Inflation Reduction Act.
The list includes Eliquis, a blood thinner marketed by Bristol Myers (NYSE:BMY) and Pfizer (NYSE:PFE); Jardiance, a diabetes therapy developed by Eli Lilly (NYSE:LLY); and Imbruvica, a blood cancer therapy marketed by AbbVie (ABBV) and Johnson & Johnson (JNJ).
Other targeted drugs include AstraZeneca's (AZN) diabetes therapy Farxiga, Novartis' (NVS) cardiovascular drug Entresto, and JNJ's (JNJ) blood thinner Xarelto and
arthritis therapy Stelara.
Merck's (NYSE:MRK) anti-diabetic medication Januvia, Amgen's (AMGN) rheumatoid arthritis therapy Enbrel and Novo Nordiskâs (NVO) (OTCPK:NONOF) insulin product
Fiasp complete the list.
The announcement marks a key step in a lengthy bargaining process between the manufacturers and the CMS before the revised drug prices take effect in 2026.
The program, challenged by leading drugmakers, including Merck (MRK) and Bristol Myers (BMY), in multiple lawsuits, is expected to save as much as $98.5B for the U.S. healthcare system over ten years.
More on Medicare price negotiations

Analysts rule out major industry impact from drug pricing negotiations
J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg
Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations
Medicare revises guidance on drug price negotiations amid lawsuits
US Chamber of Commerce sues US government over drug pricing program
Merck sues US Government to halt Medicare drug pricing program